A Phase Ib, Open-Label Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination with Vemurafenib or Vemurafenib Plus Cobimetinib in Patients with BRAFV600-Mutation Positive Metastatic Melanoma Positive Metastatic Melanoma
MD Anderson Study Status
Atezolizumab, Cobimetinib, Vemurafenib
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in participants with BRAFV600-mutation positive metastatic melanoma. Enrolled participants may continue treatment until they are no longer experiencing clinical benefit as assessed by the investigator and in alignment with the protocol.
Information and next steps
Melanoma Medical Oncology
For general questions about clinical trials: